1. Home
  2. IMVT vs ACLS Comparison

IMVT vs ACLS Comparison

Compare IMVT & ACLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMVT
  • ACLS
  • Stock Information
  • Founded
  • IMVT 2018
  • ACLS 1995
  • Country
  • IMVT United States
  • ACLS United States
  • Employees
  • IMVT N/A
  • ACLS N/A
  • Industry
  • IMVT Biotechnology: Biological Products (No Diagnostic Substances)
  • ACLS Industrial Machinery/Components
  • Sector
  • IMVT Health Care
  • ACLS Technology
  • Exchange
  • IMVT Nasdaq
  • ACLS Nasdaq
  • Market Cap
  • IMVT 2.8B
  • ACLS 2.3B
  • IPO Year
  • IMVT N/A
  • ACLS 2000
  • Fundamental
  • Price
  • IMVT $16.95
  • ACLS $73.50
  • Analyst Decision
  • IMVT Buy
  • ACLS Buy
  • Analyst Count
  • IMVT 10
  • ACLS 7
  • Target Price
  • IMVT $40.14
  • ACLS $138.00
  • AVG Volume (30 Days)
  • IMVT 1.4M
  • ACLS 658.4K
  • Earning Date
  • IMVT 08-05-2025
  • ACLS 07-30-2025
  • Dividend Yield
  • IMVT N/A
  • ACLS N/A
  • EPS Growth
  • IMVT N/A
  • ACLS N/A
  • EPS
  • IMVT N/A
  • ACLS 5.46
  • Revenue
  • IMVT N/A
  • ACLS $958,056,000.00
  • Revenue This Year
  • IMVT N/A
  • ACLS N/A
  • Revenue Next Year
  • IMVT N/A
  • ACLS $7.62
  • P/E Ratio
  • IMVT N/A
  • ACLS $13.37
  • Revenue Growth
  • IMVT N/A
  • ACLS N/A
  • 52 Week Low
  • IMVT $12.72
  • ACLS $40.40
  • 52 Week High
  • IMVT $34.47
  • ACLS $158.61
  • Technical
  • Relative Strength Index (RSI)
  • IMVT 60.86
  • ACLS 66.87
  • Support Level
  • IMVT $15.80
  • ACLS $68.51
  • Resistance Level
  • IMVT $17.06
  • ACLS $74.15
  • Average True Range (ATR)
  • IMVT 0.68
  • ACLS 2.53
  • MACD
  • IMVT 0.07
  • ACLS 0.15
  • Stochastic Oscillator
  • IMVT 86.70
  • ACLS 88.78

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

About ACLS Axcelis Technologies Inc.

Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.

Share on Social Networks: